| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Dr. Henningfield is Vice President, Research and Health Policy, Pinney Associates, Bethesda, MD; Professor, Adjunct, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Dr. Fant is Director, Clinical Pharmacology, Pinney Associates, Bethesda, MD.
Dr. Buchhalter is Scientist, Pinney Associates, Bethesda, MD. Dr. Stitzer is Professor, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Approximately 50% of long-term cigarette smokers die prematurely from the adverse effects of smoking, including on cancer, cardiovascular disease, lung disease, or other illness. This risk can be substantially reduced by smoking cessation, with greater benefits occurring the earlier in the smoking career that cessation occurs. However, cessation provides benefits at any stage, including after the onset of smoking-related disease, by improving the prognosis and quality of life. Clinicians can have a significant impact on reducing tobacco use by their patients by following the US Public Health Service Clinical Practice Guidelines. Proven strategies include structured methods of advising cigarette smokers to quit and guidance to facilitate their efforts, as well as the use of various pharmacotherapies. Pharmacotherapies for tobacco dependence include nicotine replacement medications in the form of gum, transdermal patch, lozenge, sublingual tablet, nasal spray, and vapor inhaler formulations. The only nonnicotine medication that has been approved by the US Food and Drug Administration is bupropion. Combination therapies, long-term medication therapies, and harm reduction strategies may further improve outcome with approved medications. Further, new medications such as varenicline and rimonabant are likely to reach tobacco users who are refractory to current treatments. Increasing the treatment options, increasing availability, and reducing the perceived cost of these medications may have an additional public health impact.
This article has been cited by other articles:
|
|
 |
|
  C. A. Oncken and H. R. Kranzler What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res, November 1, 2009; 11(11): 1265 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Carrozzi, F. Pistelli, and G. Viegi Review: Pharmacotherapy for smoking cessation Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 301 - 317. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Schmelzle, W. W. Rosser, and R. Birtwhistle Update on pharmacologic and nonpharmacologic therapies for smoking cessation Can Fam Physician, July 1, 2008; 54(7): 994 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Paterson, S. Vlachou, S. Guery, K. Kaupmann, W. Froestl, and A. Markou Positive Modulation of GABAB Receptors Decreased Nicotine Self-Administration and Counteracted Nicotine-Induced Enhancement of Brain Reward Function in Rats J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Le Foll MD PhD and T. P. George MD Treatment of tobacco dependence: integrating recent progress into practice Can. Med. Assoc. J., November 20, 2007; 177(11): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fossati, G. Apolone, E. Negri, A. Compagnoni, C. La Vecchia, S. Mangano, L. Clivio, S. Garattini, and for the General Practice Tobacco Cessation Investi A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care Arch Intern Med, September 10, 2007; 167(16): 1791 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 56S - 68S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M . Sullivan, S. M. Seed, and R. J. DeBellis State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations American Journal of Lifestyle Medicine, May 1, 2007; 1(3): 201 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 S J. Henley, C. J Connell, P. Richter, C. Husten, T. Pechacek, E. E Calle, and M. J Thun Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco Tob. Control, February 1, 2007; 16(1): 22 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D Hall A research agenda for assessing the potential contribution of genomic medicine to tobacco control Tob. Control, February 1, 2007; 16(1): 53 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L Zierler-Brown and J. A Kyle Oral Varenicline for Smoking Cessation Ann. Pharmacother., January 1, 2007; 41(1): 95 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagai, M. Ito, N. Nakamichi, H. Mizoguchi, H. Kamei, A. Fukakusa, T. Nabeshima, K. Takuma, and K. Yamada The Rewards of Nicotine: Regulation by Tissue Plasminogen Activator-Plasmin System through Protease Activated Receptor-1. J. Neurosci., November 22, 2006; 26(47): 12374 - 12383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Cokkinides, P. Bandi, E. Ward, A. Jemal, and M. Thun Progress and opportunities in tobacco control. CA Cancer J Clin, May 1, 2006; 56(3): 135 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joshi and R. F. Tyndale INDUCTION AND RECOVERY TIME COURSE OF RAT BRAIN CYP2E1 AFTER NICOTINE TREATMENT Drug Metab. Dispos., April 1, 2006; 34(4): 647 - 652. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
